Send this to a friend

Biostage delisting effective Dec. 18

Holliston biotech Biostage will officially be delisted on Dec. 18 from the Nasdaq Stock Excahnge, after failing to keep a stock price above $1 and a $2.5 million stockholders' equity requirement, according to a new filing with the U.S. Securities & Exchange Commission.
The Nasdaq listing panel determined the company would be delisted back on May 18, but Biostage appealed that decision to a Nasdaq panel. The company was granted conditional listi ...

Fields marked in red are required
Your name
Your email
Recipient addresses
(Separate multiple addresses with commas)

Personal message

Copyright 2017 New England Business Media